Cargando…

Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease

Despite considerable advancements in medicine, the optimal treatment for chronic kidney disease (CKD), especially diabetic kidney disease (DKD), remains a major challenge. More patients with DKD succumb to death due to cardiovascular events than due to progression to end-stage renal disease (ESRD)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Murakoshi, Maki, Gohda, Tomohito, Suzuki, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139523/ https://www.ncbi.nlm.nih.gov/pubmed/32183005 http://dx.doi.org/10.3390/ijms21061957

Ejemplares similares

Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients
por: Gohda, Tomohito, et al.
Publicado: (2022)

Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes
por: Kamei, Nozomu, et al.
Publicado: (2018)

Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease
por: Gohda, Tomohito, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials
por: Gohda, Tomohito, et al.
Publicado: (2022)

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice
por: Ichikawa, Saki, et al.
Publicado: (2020)

Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function
por: Gohda, Tomohito, et al.
Publicado: (2020)

Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes
por: Murakoshi, Maki, et al.
Publicado: (2022)

Development of an In-House EphA2 ELISA for Human Serum and Measurement of Circulating Levels of EphA2 in Hypertensive Patients with Renal Dysfunction
por: Murakoshi, Maki, et al.
Publicado: (2022)

Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice
por: Murakoshi, Maki, et al.
Publicado: (2021)

Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis
por: Gohda, Tomohito, et al.
Publicado: (2017)

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs
por: Sakuma, Hiroko, et al.
Publicado: (2020)

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
por: Koshida, Takeo, et al.
Publicado: (2023)

Role of Mindin in Diabetic Nephropathy
por: Murakoshi, Maki, et al.
Publicado: (2011)

Effect of Exercise on Kidney Function, Oxidative Stress, and Inflammation in Type 2 Diabetic KK-A(y) Mice
por: Ishikawa, Yuji, et al.
Publicado: (2012)

Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy
por: Maruyama, Shuntaro, et al.
Publicado: (2016)

Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA(1c) in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria
por: Skupien, Jan, et al.
Publicado: (2014)

Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy
por: Sonoda, Yuji, et al.
Publicado: (2015)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor
por: Oshima, Megumi, et al.
Publicado: (2020)

Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus
por: Wu, Tsung-Hui, et al.
Publicado: (2022)

The effect of capsaicin on circulating biomarkers, soluble tumor necrosis factor and soluble tumor necrosis factor-receptor-1 and -2 levels in vivo using lipopolysaccharide-treated mice
por: Ijiri, Yoshio, et al.
Publicado: (2014)

Continuous extracorporeal treatments in a dialysis patient with COVID-19
por: Nihei, Yoshihito, et al.
Publicado: (2020)

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and Selected Cytokines—Potential Biomarkers in Children with Solitary Functioning Kidney
por: Nosek, Hanna, et al.
Publicado: (2021)

Combat Diabetic Nephropathy: From Pathogenesis to Treatment
por: Gohda, Tomohito, et al.
Publicado: (2014)

Pathogenesis and Novel Treatment from the Mouse Model of Type 2 Diabetic Nephropathy
por: Furukawa, Masako, et al.
Publicado: (2013)

Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
por: Yabuuchi, Junko, et al.
Publicado: (2020)

Circulating Biomarkers to Predict Diabetic Retinopathy in Patients with Diabetic Kidney Disease
por: , Jonny, et al.
Publicado: (2023)

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer
por: IGAWA, SATOSHI, et al.
Publicado: (2014)

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine
por: Fukao, Yusuke, et al.
Publicado: (2021)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Soluble Tumor Necrosis Factor-α Receptor 2 in Urine Is a Potential Biomarker for Noninvasive Diagnosis of Malaria During Pregnancy
por: Tassi Yunga, Samuel, et al.
Publicado: (2016)

Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
por: Endo, S, et al.
Publicado: (2000)

Regulation of Tumor Progression by Programmed Necrosis
por: Lee, Su Yeon, et al.
Publicado: (2018)

Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis
por: Udomsinprasert, Wanvisa, et al.
Publicado: (2020)

Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1
por: Lee, Jung Eun, et al.
Publicado: (2013)

Tumor necrosis factor alpha is a promising circulating biomarker for the development of obstructive sleep apnea syndrome: a meta-analysis
por: Li, Qingsheng, et al.
Publicado: (2017)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2
por: Fischer, Roman, et al.
Publicado: (2017)

Novel biomarkers for prognosticating diabetic kidney disease progression
por: Swaminathan, Shilna Muttickal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rl7h0mr03hlo5a8ice73p1eb1g